Tarsus Pharmaceuticals (TARS)
(Real Time Quote from BATS)
$70.46 USD
+0.32 (0.46%)
Updated Oct 13, 2025 03:23 PM ET
After-Market: $70.34 -0.12 (-0.17%) 4:06 PM ET
4-Sell of 5 4
D Value C Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TARS 70.46 +0.32(0.46%)
Will TARS be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for TARS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARS
Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains?
Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last?
TARS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
Other News for TARS
Slingshot Bullish appears for TARS after 0.34% move
TARS makes New 52 Week Closing High on October 9
Tarsus Pharmaceuticals price target raised to $85 from $80 at BofA
Tarsus Pharmaceuticals price target raised by $5 at BofA, here's why
New 52 Week Closing High appears for TARS after 1.94% move